Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Free Cash Flow (2016 - 2021)

GT Biopharma (GTBP) has disclosed Free Cash Flow for 12 consecutive years, with -$3.7 million as the latest value for Q4 2021.

  • On a quarterly basis, Free Cash Flow fell 92.27% to -$3.7 million in Q4 2021 year-over-year; TTM through Dec 2021 was -$15.6 million, a 114.9% decrease, with the full-year FY2025 number at -$12.9 million, changed 0.03% from a year prior.
  • Free Cash Flow was -$3.7 million for Q4 2021 at GT Biopharma, up from -$3.9 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$4000.0 in Q3 2018 to a low of -$4.3 million in Q2 2021.
  • A 5-year average of -$2.0 million and a median of -$1.8 million in 2020 define the central range for Free Cash Flow.
  • Peak YoY movement for Free Cash Flow: soared 99.82% in 2018, then tumbled 28050.0% in 2019.
  • GT Biopharma's Free Cash Flow stood at -$2.2 million in 2017, then surged by 99.81% to -$4000.0 in 2018, then plummeted by 11925.0% to -$481000.0 in 2019, then plummeted by 300.62% to -$1.9 million in 2020, then crashed by 92.27% to -$3.7 million in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Free Cash Flow are -$3.7 million (Q4 2021), -$3.9 million (Q3 2021), and -$4.3 million (Q2 2021).